Dentsply Sirona

Dentsply Sirona (NYSE: XRAY) + reported Street-beating Q2 results and upped its full-year guidance, citing solid performance across its business segments.

The Charlotte, North Carolina–based dental products and equipment company yesterday evening reported a net income of $86 million, or 40¢ per share, on sales of $1.028 billion for the three months ended June 30, 2023. Earnings were up 17.8%, and revenue more modestly rose 0.5% compared to Q2 2022.

Adjusted to exclude one-time items, Dentsply Sirona had earnings per share of 51¢. The result was 8¢ ahead of The Street, where analysts expected EPS of 43¢ and $998.96 million in revenue.

“We are pleased with our second quarter results, the highlight of which was organic growth in all four segments. Notably, aligners delivered another quarter of double-digit growth and our business in China returned to growth. We continue to see healthy patient traffic in…

Dentsply Sirona (Nasdaq:XRAY) shares fell today despite first-quarter results that came in ahead of the consensus forecast.

Shares of XRAY fell 2.9% at $40.88 apiece in early-morning trading today. MassDevice’s MedTech 100 Index — which includes stocks of the world’s largest medical device companies — rose 0.4%.

The Charlotte, North Carolina-based dental equipment and supplies maker posted losses of $19 million. That amounts to losses of 9¢ per share, on sales of $978 million for the three months ended March 31, 2023.

Dentsply recorded an $80 million bottom-line slide into the red despite sales growth of 1%. The company attributed a large chunk of its net loss to restructuring-related charges and other costs totaling $71 million net of tax. Dentsply enacted its restructuring plan in February, laying off 10% of its workforce and changing its operating model.

Adjusted to exclude one-time items, earnings per share totaled 39¢. That landed…

Dentsply Sirona this week announced fourth-quarter results that beat the overall consensus on Wall Street.

The Charlotte, N.C.-based company reported net losses of $15 million, or -7¢ per share, on sales of $983 million, for the three months that ended December 31, 2022. It had a sales loss of 10.88% compared with Q4 2022 and a profit loss from the same period when it reported $119 million in profits.

Adjusted to exclude one-time items, earnings per share were 46¢ per share, 14¢ ahead of The Street, where analysts were looking for sales of $941.37 million.

“2022 was a challenging year due to both internal and external factors. Despite these challenges, we were pleased to deliver fourth-quarter financial results that exceeded the high end of our prior sales and EPS outlook ranges. This represents an important milestone as the company works to improve performance and rebuild investor and employee confidence,” CEO Simon Campion said in a news release.

Dentsply Sirona (Nasdaq:XRAY) shares took a slight hit today on third-quarter results that came up shy of the consensus forecast.

The Charlotte, North Carolina-based dental equipment and supplies maker posted losses of $1.1 billion in the quarter. That amounts to $5.01 per share on sales of $947 million for the three months ended Sept. 30, 2022.

Dentsply Sirona reported a massive bottom-line slide into the red on a sales decline of 8.9%. In addition, it recorded a non-cash charge for “the impairment of goodwill and intangible assets” worth $1.1 billion. The company attributed this to macroeconomic factors resulting from weakened global demand and higher cost of capital.

Additionally, it felt the effects of unfavorable foreign currency impacts and increased raw material, supply chain and service costs. These contributed to reduced revenue expectations and lowered expectations for future cash flows.

Adjusted to exclude one-time items, ea…

Dentsply Sirona (Nasdaq: XRAY) announced today that its board’s audit committee found no evidence of intentional wrongdoing or fraud on the part of its former CEO or CFO.

The dental tech company fired former CEO Don Casey in April. Previous CFO Jorge Gomez soon left his new job at Moderna. Former BD executive Simon Campion is now CEO, with former Integra Lifesciences COO Glenn Coleman joining as CFO in September.

Dentsply Sirona had already disclosed to the SEC that it was investigating the use of incentives to sell products to distributors during the third and fourth quarters of 2021. Even though the company board’s internal inquiry is over, the SEC continues to look into matters at the company, Dentsply Sirona said in a Form 8-K filed Oct. 29.

Though the board’s investigation found no evidence of intentional wrongdoing or fraud by Casey or Gomez, it did find that they violated the company’s code of ethics and business conduct. Read more

Dentsply Sirona (Nasdaq:XRAY) announced today that it is launching new products and solutions, including the new Primescan Connect.

The company said in a news release that it expects the product launches to “bring dentistry to a new level.”

Primescan Connect is a laptop-based version of the company’s cart-based Primescan intraoral scanner. It is powered by the cloud platform DS Core, which now has new features, as well as the DS Core Care service program.

The platform offers highly connective 3D scanning technology for a lower investment. The laptop aspect offers flexibility and space-saving when not in use. Plus, Dentsply said it fosters collaboration with any lab through validated workflows to all major lab software.

Primescan Connect can be used for digital workflows such as restorative indications, implantology, orthodontics and sleep appliances. Dentsply said the innovative device can increase efficiency and improve the pati…